COVID-19 OUTPATIENT TREATMENT GUIDELINES ROADMAP

Last updated: July 4, 2023

This roadmap is not intended to represent a prioritization of therapeutic strategies. For information on prioritization of one outpatient treatment over another, see NIH's guidelines on the therapeutic management of non-hospitalized adults with COVID-19 and ASHP Clinical Decision Aid.

Does your patient have COVID-19?

YES
NO

Hospitalized patient? 

YES
NO

Is your patient age 18 or older?

YES
NO

Dosing: 250 mL high-titer convalescent plasma

YES
NO

Does your patient have any symptoms?

YES
NO

Does patient have prior COVID-19 infection?

YES
NO

Does your patient meet any of the following criteria?

• Is patient age 65 years and older?
• Does patient have chronic lung disease?
• Does patient have heart or solid organ transplantaion?
• Does patient have diabetes or severe immunosuppression?
• Does patient have obesity BMI of more than 25 kg/m^2?
• Does patient have pregnancy?
• Does patient have hypertension?
• Does patient have neurodevelopmental disorders?
• Does patient have chronic kidney disease?
• Does patient have any symptoms?  

YES
NO

Does your patient have any symptoms from COVID-19?

YES
NO

Does your patient have an underlying medical condition that places them at a higher risk for progression of COVID-19?

YES
NO

High-titer convalescent plasma

YES
NO

Remdesivir (Veklury®) 

YES
NO

Nirmatrelvir (Paxlovid®) 

YES
NO

Molnupiravir (Lopinavir) 

YES
NO

When giving products under Emergency Use Authorization, provide note:

2. Inform patient that this is an unapproved drug.
3. Inform patient that this is an unapproved drug.

Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma (nih.gov)

Outpatients Trial: Early Use of High-titer Convalescent Plasma in and molnupiravir:

Additional information on where to access these therapeutics can be found at the FDA’s Emergency Use Authorization, and guideline recommendations Information) with the extended approval for outpatient therapeutic management of non-hospitalized adults with COVID-19.

References

8. Convalescent Plasma FDA fact sheet and list of tests and categories of high, low, and moderate risk for COVID-19: https://www.fda.gov/media/141477/download
9. Emegency Use Authorization for molnupiravir: https://www.fda.gov/media/141477/download